1. Search Result
Search Result
Isoforms Recommended: nNOS
Results for "

nNOS

" in MedChemExpress (MCE) Product Catalog:

40

Inhibitors & Agonists

3

Peptides

3

Natural
Products

1

Isotope-Labeled Compounds

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W022047

    NO Synthase Cardiovascular Disease Neurological Disease
    nNOS-IN-1(Compound 14) is an inhibitor for nitric oxide synthases (NOS), that exhibits inhibitory activities against neuroal, inducible and endothelial NOS, with IC50s of 2.5, 5.7 and 13 μM, respectively .
    nNOS-IN-1
  • HY-W007524

    2-Quinolinamine

    NO Synthase Orthopoxvirus Infection Neurological Disease
    2-Aminoquinoline (2-Quinolinamine) is a promising compound as bioavailable nNOS inhibitor but suffers from low human nNOS inhibition, low selectivity versus human eNOS, and significant binding to other CNS targets. 2-Aminoquinoline exhibits antiviral activity against the vaccinia virus. 2-Aminoquinoline has the potential for the research of antineurodegenerative agents .
    2-Aminoquinoline
  • HY-124996

    NO Synthase Neurological Disease Inflammation/Immunology Cancer
    (Rac)-ZLc-002, an inhibitor of nNOS interaction with nitric oxide synthase 1 adaptor protein (NOS1AP), suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with Paclitaxel (HY-B0015) to reduce tumor cell viability .
    (Rac)-ZLc-002
  • HY-B1478

    Histamine Receptor NO Synthase Endocrinology
    Dimaprit dihydrochloride is a selective histamine H2 receptor agonist, it also inhibits nNOS with an IC50 of 49 μM. Dimaprit dihydrochloride can stimulate gastric acid secretion .
    Dimaprit dihydrochloride
  • HY-B0503

    Thiouracil

    NO Synthase Endocrinology Cancer
    2-Thiouracil (Thiouracil) is an antithyroid compound. 2-Thiouracil can function as a highly specific melanoma seeker. 2-Thiouracil is a selective inhibitor of neuronal nitric oxide synthase (nNOS) with a Ki of 20 μM .
    2-Thiouracil
  • HY-101316

    NO Synthase Neurological Disease
    TRIM is a potent nitric oxide synthase inhibitor. TRIM inhibits mouse cerebellar nNOS and rat lung iNOS in vitro with IC50 values of 28.2 and 27.0 µM, respectively. Antidepressant- and anxiolytic-like effects .
    TRIM
  • HY-100457
    IC87201
    2 Publications Verification

    iGluR Neurological Disease
    IC87201, an inhibitor of PSD95-nNOS protein-protein interactions, suppresses NMDAR-dependent NO and cGMP formation.
    IC87201
  • HY-115750

    NO Synthase Neurological Disease
    Nω-allyl-L-arginine is a competitive and reversible inhibitor of bovine brain nitric oxide synthase (nNOS). Nω-allyl-L-arginine can inactivate nNOS in a time-dependent manner. Nω-allyl-L-arginine also is a substrate, producing L-arginine, acrolein, and H2O .
    Nω-allyl-L-arginine
  • HY-115410

    NO Synthase Metabolic Disease
    NG-Amino-L-arginine hydrochloride induces inactivation of the citrulline-forming activity of the nNOS, iNOS, and eNOS isoforms with Ki values of 0.3 μM, 3 μM, and 2.5 μM, respectively .
    NG-Amino-L-arginine hydrochloride
  • HY-135224

    1,4-PB-ITU dihydrobromide

    NO Synthase Cancer
    1,4-PBIT (1,4-PB-ITU) dihydrobromide (compound 46) is a potent nitric oxide synthases (NOS) inhibitor, with Ki values of 7.6 nM, 360 nM, and 16 nM for the inducible (iNOS), endothelial (eNOS), and neuronal (nNOS) isozymes, respectively .
    1,4-PBIT dihydrobromide
  • HY-W484263

    NO Synthase Neurological Disease
    hnNOS-IN-3 (compound 39) is a selective nNOS inhibitor, with a Ki of 0.32 μM. The nNOS binding of hnNOS-IN-3 is competitive with L-arginine. The selectivity of hnNOS-IN-3 for nNOS versus iNOS (Ki=37 μM) and eNOS (Ki=9.4 μM) is 115-fold and 29-fold, respectively .
    hnNOS-IN-3
  • HY-155355

    iGluR Neurological Disease
    LY836 is an orally active neuroprotective agent. LY836 significantly blocks PSD95-nNOS association in cortical neurons. LY836 can be used in study ischemic stroke .
    LY836
  • HY-102062
    Nω-Propyl-L-arginine
    1 Publications Verification

    N-omega-Propyl-L-arginine

    NO Synthase Neurological Disease
    Nω-Propyl-L-arginine (N-omega-Propyl-L-arginine) is a potent, competitive, and highly selective inhibitor of neuronal nitric oxide synthase (nNOS), with a Ki of 57 nM. Nω-Propyl-L-arginine displays a 149-fold selectivity for nNOS over endothelial NOS (eNOS) .
    Nω-Propyl-L-arginine
  • HY-102062A
    Nω-Propyl-L-arginine hydrochloride
    1 Publications Verification

    N-omega-Propyl-L-arginine hydrochloride

    NO Synthase Neurological Disease
    Nω-Propyl-L-arginine (N-omega-Propyl-L-arginine) hydrochloride is a potent, competitive, and highly selective inhibitor of neuronal nitric oxide synthase (nNOS), with a Ki of 57 nM. Nω-Propyl-L-arginine hydrochloride displays a 149-fold selectivity for nNOS over endothelial NOS (eNOS) .
    Nω-Propyl-L-arginine hydrochloride
  • HY-W003969

    Ascensil

    NO Synthase Others
    Aminopicoline (Ascensil) is a potent and nonselective inhibitor of NO synthase (NOS) isoenzymes (iNOS, nNOS, eNOS) .
    Aminopicoline
  • HY-100456

    iGluR Neurological Disease
    ZL006 is a potent inhibitor of nNOS/PSD-95 interaction, and inhibits NMDA receptor-mediated NO synthesis.
    ZL006
  • HY-139135

    NO Synthase Others
    Methyl-L-NIO (compound 2d) hydrochloride is a potential selective inhibitor (IC50: 70 μM) of dimethylarginine dimethylaminohydrolase hDDAH. Methyl-L-NIO also has inhibitory activity against NO synthase. The inhibition rates of Methyl-L-NIO on different isoforms of NO synthase at a concentration of 100 μM are 77% (nNOS), 20% (eNOS), and 72% (iNOS) respectively; the inhibition rates at a concentration of 1 mM are 100% (nNOS), 85% (eNOS), 100% (iNOS) .
    Methyl-L-NIO hydrochloride
  • HY-W003969R

    NO Synthase Others
    Aminopicoline (Standard) is the analytical standard of Aminopicoline. This product is intended for research and analytical applications. Aminopicoline (Ascensil) is a potent and nonselective inhibitor of NO synthase (NOS) isoenzymes (iNOS, nNOS, eNOS) .
    Aminopicoline (Standard)
  • HY-69019
    7-Nitroindazole
    1 Publications Verification

    NO Synthase Cardiovascular Disease Neurological Disease
    7-Nitroindazole is a selective nNOS inhibitor with antinociceptive and cardiovascular effects. 7-Nitroindazole is a useful tool to evaluate the biological roles of nitric oxide in the central nervous system .
    7-Nitroindazole
  • HY-69019A

    NO Synthase Cardiovascular Disease Neurological Disease
    7-Nitroindazole sodium is a selective nNOS inhibitor with antinociceptive and cardiovascular effects. 7-Nitroindazole sodium is a useful tool to evaluate the biological roles of nitric oxide in the central nervous system .
    7-Nitroindazole sodium
  • HY-147306A

    NO Synthase Neurological Disease
    (S)-ZLc002 is a S-enantiomer of ZLc-002. ZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain .
    (S)-ZLc002
  • HY-122060

    NO Synthase Metabolic Disease
    BYK 191023 is a selective and L-arginine competitive inducible nitric-oxide synthase inhibitor with an IC50 value of 86 nM, 17 µM, 162 µM for inducible (iNOS), neuronal (nNOS), and endothelial (eNOS) NO synthases respectively .
    BYK 191023
  • HY-147306

    Others Neurological Disease
    ZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain. ZLc-002 can be used for the research of anxiety disorder and inflammation .
    ZLc-002
  • HY-120865

    NO Synthase Inflammation/Immunology
    1,3-PBIT is a potent inhibitor of iNOS with a Ki of 47 nM compared to Ki values for eNOS and nNOS are 9 and 0.25 μM, respectively, for the purified human enzymes. Its inhibition in whole cells is greatly diminished, presumably to poor membrane permeability.
    1,3-PBIT dihydrobromide
  • HY-18732A
    L-NMMA acetate
    5 Publications Verification

    Tilarginine acetate; Methylarginine acetate

    NO Synthase Endogenous Metabolite Cardiovascular Disease Cancer
    L-NMMA acetate is a nitric oxide synthase inhibitor of all NOS isoforms including NOS1, NOS2, and NOS3. The Ki values for nNOS (rat), eNOS (human), and iNOS (mouse) are approximately 0.18, 0.4, and 6 µM, respectively.
    L-NMMA acetate
  • HY-138564

    NO Synthase Inflammation/Immunology
    NOS-IN-1 is a potent and orally active NO synthase (NOS) isoforms inhibitor with IC50s of 0.1 μM, 1.1 μM, and 0.2 μM for human iNOS (hiNOS), heNOS and hnNOS, respectively .
    NOS-IN-1
  • HY-100986
    L-NIO dihydrochloride
    1 Publications Verification

    NO Synthase Cardiovascular Disease
    L-NIO dihydrochloride is a potent, non-selective and NADPH-dependent nitric oxide synthase (NOS) inhibitor, with Kis of 1.7, 3.9, 3.9 μM for neuronal (nNOS), endothelial (eNOS), and inducible (iNOS), respectively . L-NIO dihydrochloride induces a consistentfocal ischemic infarctin rats .
    L-NIO dihydrochloride
  • HY-100986B

    NO Synthase Cardiovascular Disease
    L-NIO is a potent, non-selective and NADPH-dependent nitric oxide synthase (NOS) inhibitor, with Kis of 1.7, 3.9, 3.9 μM for neuronal (nNOS), endothelial (eNOS), and inducible (iNOS), respectively . L-NIO induces a consistentfocal ischemic infarctin rats .
    L-NIO
  • HY-101175

    NO Synthase Neurological Disease
    3-Bromo-7-nitroindazole is a more potent and selective inhibitor of neuronal nitric oxide synthase (nNOS) than eNOS or inducible nitric oxide synthase (iNOS). 3-Bromo-7-nitroindazole affects the intercellular messenger nitric oxide (NO) synthesis throughout the body and brain .
    3-Bromo-7-nitroindazole
  • HY-B0503S

    Thiouracil-13C,15N2

    Isotope-Labeled Compounds NO Synthase Endocrinology Cancer
    2-Thiouracil- 13C, 15N2 is the 13C, 15N labeled 2-Thiouracil. 2-Thiouracil (Thiouracil) is an antithyroid compound. 2-Thiouracil can function as a highly specific melanoma seeker. 2-Thiouracil is a selective inhibitor of neuronal nitric oxide synthase (nNOS) with a Ki of 20 μM.
    2-Thiouracil-13C,15N2
  • HY-18399

    HSP NO Synthase Cancer
    YM-1 is a stable and soluble MKT-077 (HY-15096) analog and an orally active Hsp70 inhibitor. YM-1 induces cell death of HeLa cells and up-regulates the level of p53 and p21 proteins .
    YM-1
  • HY-148417

    Serotonin Transporter Neurological Disease
    ZZL-7 is a fast-onset antidepressant agent. ZZL-7 works by disrupting the interaction between the serotonin transporter (SERT) and neuronal nitric oxide synthase (nNOS) in the dorsal raphe nucleus (DRN). ZZL-7 can cross the blood-brain barrier readily. ZZL-7 can be used for the research of major depressive disorder (MDD) .
    ZZL-7
  • HY-14602

    Homotaurine; 3-Amino-1-propanesulfonic acid

    Amyloid-β Cancer
    Tramiprosate (Homotaurine), an orally active and brain-penetrant natural amino acid found in various species of red marine algae. Tramiprosate binds to soluble Aβ and maintains Aβ in a non-fibrillar form. Tramiprosate is also a GABA analog and possess neuroprotection, anticonvulsion and antihypertension effects .
    Tramiprosate
  • HY-14602R

    Amyloid-β Cancer
    Tramiprosate (Standard) is the analytical standard of Tramiprosate. This product is intended for research and analytical applications. Tramiprosate (Homotaurine), an orally active and brain-penetrant natural amino acid found in various species of red marine algae. Tramiprosate binds to soluble Aβ and maintains Aβ in a non-fibrillar form. Tramiprosate is also a GABA analog and possess neuroprotection, anticonvulsion and antihypertension effects .
    Tramiprosate (Standard)
  • HY-130452

    NO Synthase Neurological Disease
    NOS1-IN-1 is a selective and cell-permeable nNOS inhibitor with a Ki of 120 nM. NOS1-IN-1 exhibits 2617-fold and 325-fold selectivity over eNOS (Ki=39 μM) and iNOS (Ki=325 μM) , respectively . NOS1-IN-1 can be used for the research of neurological disease, including cerebral palsy (CP) .
    NOS1-IN-1
  • HY-12119
    GW274150
    2 Publications Verification

    NO Synthase Neurological Disease Inflammation/Immunology
    GW274150 is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50=2.19 μM; Kd=40 nM) and rat iNOS (ED50=1.15 μM). GW274150 also displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 exerts a protective role in an acute model of lung injury inflammation .
    GW274150
  • HY-12119A
    GW274150 phosphate
    2 Publications Verification

    NO Synthase Neurological Disease Inflammation/Immunology
    GW274150 phosphate is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50=2.19 μM; Kd=40 nM) and rat iNOS (ED50=1.15 μM). GW274150 phosphate displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 phosphate exerts a protective role in an acute model of lung injury inflammation .
    GW274150 phosphate
  • HY-12119B

    NO Synthase Neurological Disease Inflammation/Immunology
    GW274150 (dihydrochloride) is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50=2.19 μM; Kd=40 nM) and rat iNOS (ED50=1.15 μM). GW274150 (dihydrochloride) displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 (dihydrochloride) exerts a protective role in an acute model of lung injury inflammation .
    GW274150 dihydrochloride
  • HY-P0117A
    Tat-NR2B9c TFA
    Maximum Cited Publications
    8 Publications Verification

    Tat-NR2Bct TFA; NA-1 TFA

    iGluR NO Synthase Neurological Disease
    Tat-NR2B9c TFA (Tat-NR2Bct TFA) is a postsynaptic density-95 (PSD-95) inhibitor, with EC50 values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c TFA disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC50 values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c TFA also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy .
    Tat-NR2B9c TFA
  • HY-P0117
    Tat-NR2B9c
    Maximum Cited Publications
    8 Publications Verification

    Tat-NR2Bct; NA-1

    iGluR NO Synthase Neurological Disease
    Tat-NR2B9c (Tat-NR2Bct; NA-1) is a postsynaptic density-95 (PSD-95) inhibitor, with EC50 values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC50 values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c also inhibits?neuronal nitric oxide synthase (nNOS)/PSD-95?interaction, and possesses neuroprotective efficacy .
    Tat-NR2B9c

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: